Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Bullboard Posts
Post by narinderon Jun 26, 2000 3:14pm
462 Views
Post# 2118529

Excerpts from Stockhouse Interview

Excerpts from Stockhouse InterviewFor the newbies here..the following is excerpts from the stockhouse intervies\w: "In its March Q2 report, Conac announced a 38% increase in revenues, to $1,273,000, for the period ending January 31, 2000. With Q3 results due out at the end of this month, CEO Jacqueline Michael is forecasting more good news. "There's definitely revenue growth from the last quarter as well as from last year," says Michael. "Compared to last year, it's phenomenal." "We are looking at an extremely broad vision for this company. I can't disclose too much but we're really looking very seriously at taking this company to a completely new level," she enthuses. "Acquisitions may play a role in the move to this new level. Tom D'Sena, vice-president development and marketing is enthusiastic about the company's current acquisition prospects, "Some of the companies are kind of a fair size compared to ourselves so it will be a fairly major acquisition." D'Sena is confident that Conac will be announcing the agreements and that they will be done deals. He also says the announcements "will definitely be before six months." "Conac believes its project management software leads the industry and if Q3 growth is truly "phenomenal," this Canadian small cap may prove to be a worthy long-term investment for the risk-tolerant investor. "We are positioning the company for very substantial growth and everything should come into play, I would say in the next three to six months," says D'Sena.
Bullboard Posts